REFERENCES

1. Hall JE, Hall ME. *Guyton and Hall Textbook of Medical Physiology*. 14th ed. Philadelphia: Saunders; 2021:335–438.
2. Patton KT. Urinary system. In: *Human Physiology*. 10th ed. St. Louis: Elsevier; 2016:963–995.
3. Green T, et al. The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function. *Curr Opin Nephrol Hypertens*. 2012;21(1):7–14.
4. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. *J Cardiol*. 2010;56(3):262–270.
5. Sands JM, et al. In: Yu ASL, et al., ed. *Brenner & Rector's The Kidney*. 11th ed. Philadelphia: Elsevier; 2020:274–302.
6. Wagener G, Brentjens TE. Anesthetic concerns in patients presenting with renal failure. *Anesthesiol Clin*. 2010;28(1):39–54.
7. Wu Y, Jin S, Zhang L, et al. Minimum Alveolar concentration-Awake of sevoflurane is decreased in patients with end-stage renal disease. *Anesth Analg*. 2019;128:77.
8. Tobias JD. Inhalational anesthesia: basic pharmacology, end organ effects, and applications in the treatment of status asthmaticus. *J Intensive Care Med*. 2009;24:361–371.
9. Forman S, Ishizawa Y. Inhaled anesthetic pharmacokinetics: uptake, distribution, metabolism and toxicity. In: Gropper MA, et al., ed. *Miller's Anesthesia*. 9th ed. Philadelphia: Elsevier; 2020:509–539.
10. Kharasch ED, et al. New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 1). *Anesthesiology*. 2006;105(4):726–736.
11. Sondekoppam RV, Narsingani KH, Schimmel TA, McConnell BM, Buro K, Özelsel TJ. The impact of sevoflurane anesthesia on postoperative renal function: a systematic review and meta-analysis of randomized-controlled trials. *Can J Anaesth*. 2020. 10.1007/s12630-020-01791-5.
12. Brienza N, et al. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. *Crit Care Med*. 2009;37(6):2079–2090.
13. Wu X, Jiang Z, Ying J, et al. Optimal blood pressure decreases acute kidney injury after gastrointestinal surgery in elderly hypertensive patients: a randomized study: optimal blood pressure reduces acute kidney injury. *J Clin Anesth*. 2017;43:77.
14. Mathis MR, Naik BI, Freundlich RE, et al. Preoperative risk and the association between hypotension and postoperative acute kidney injury. *Anesthesiology*. 2020;132(3):461–475.
15. Sharrock NE, et al. Hypotensive epidural anaesthesia in patients with preoperative renal dysfunction undergoing total hip replacement. *Br J Anaesth*. 2006;96(2):207–212.
16. Tattersall J. EBPG guideline on dialysis strategies. *Nephrol Dial Transplant*. 2007;22(suppl 2):ii5–ii21.
17. Milosavljevic SB, et al. Influence of spinal and general anesthesia on the metabolic, hormonal, and hemodynamic response in elective surgical patients. *Med Sci Monit*. 2014;20:1833–1840.
18. Rosenberg PH, et al. Maximum recommended doses of local anesthetics: a multifactorial concept. *Reg Anesth Pain Med*. 2004;29(6):564–575.
19. Nishiyama T. Stress hormone changes in general anesthesia of long duration: isoflurane-nitrous oxide vs. sevoflurane-nitrous oxide anesthesia. *J Clin Anesth*. 2005;17(8):586–591.
20. Ledowski T. Neuroendocrine stress response and heart rate variability: a comparison of total intravenous versus balanced anesthesia. *Anesth Analg*. 2005;101(6):1700–1705.
21. Tabucanon T, Tang WHW. Right heart failure and Cardiorenal syndrome. *Cardiol Clin*. 2020;38(2):185–202.
22. Bao LL, Jiang WQ, Sun FJ, et al. The influence of psychological stress on arginine vasopressin concentration in the human plasma and cerebrospinal fluid. *Neuropeptides*. 2014;48(6):361–369.
23. Huiku M, et al. Assessment of surgical stress during general anaesthesia. *Br J Anaesth*. 2007;98(4):447–455.
24. Das W, Bhattacharya S, Ghosh S, et al. Comparison between general anesthesia and spinal anesthesia in attenuation of stress response in laparoscopic cholecystectomy: a randomized prospective trial. *Saudi J Anaesth*. 2015;9:184.
25. Khan KS, et al. Pharmacology of anaesthetic agents II: inhalation anaesthetic agents. *Contin Educ Anaesthesia Crit Care Pain*. 2014;14(3):106–111.
26. Cook TL, et al. A comparison of renal effects and metabolism of sevoflurane and methoxyflurane in enzyme-induced rats. *Anesth Analg*. 1975;54(6):829–835.
27. Koblin DD, et al. I-653 resists degradation in rats. *Anesth Analg*. 1988;67(6):534–538.
28. Jones RM, et al. Biotransformation and hepato-renal function in volunteers after exposure to desflurane (I-653). *Br J Anaesth*. 1990;64(4):482–487.
29. Pavkov ME, Harding JL, Burrows NR. Trends in Hospitalizations for acute kidney injury - United States, 2000-2014. *MMWR Morb Mortal Wkly Rep*. 2018;67:289.
30. Siew ED, Deger SM. Recent advances in acute kidney injury epidemiology. *Curr Opin Nephrol Hypertens*. 2012;21(3):309–317.
31. Golden D, et al. Peri-operative renal dysfunction: prevention and management. *Anaesthesia*. 2016;71(suppl 1):51–57.
32. Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. *Kidney Int*. 2012;81(9):819–825.
33. Sileanu FE, et al. AKI in low-risk versus high-risk patients in intensive care. *Clin J Am Soc Nephrol*. 2015;10(2):187–196.
34. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2:8.
35. Alge JL, et al. Urinary angiotensinogen and risk of severe AKI. *Clin J Am Soc Nephrol*. 2013;8(2):184–193.
36. Rifkin DE, Does AKI. Truly lead to CKD? *J Am Soc Nephrol*. 2012;23:979–984.
37. Jorres A, et al. Fluid overload in acute kidney injury. In: Turner N, et al., eds. *Oxford Textbook of Clinical Nephrology*. 4th ed. London: Oxford University Press; 2016:1943.
38. Kim M, et al. Variations in the risk of acute kidney injury across intraabdominal surgery procedures. *Anesth Analg*. 2014;119(5):1121–1132.
39. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382:339.
40. Noor S, Usmani A. Postoperative renal failure. *Clin Geriatr Med*. 2008;24(4):721–729. 39.
41. Wanderer JP, Rathmell JP. Postoperative acute kidney injury: risk factors and possible interventions. *Anesthesiology*. 2016;124(5):A21.
42. Schaffer AC. Postoperative renal failure and hyponatremia. *Hosp Med Clin*. 2012;1(4):471–487.
43. Butcher BW, Liu KD. Fluid overload in AKI. *Curr Opin Crit Care*. 2012;18(00):1–6.
44. Ricci Z, et al. Perioperative intravascular volume replacement and kidney insufficiency. *Best Pract Res Clin Anaesthesiol*. 2012;26(4):463–474.
45. Gonzalez Suarez ML, Kattah A, Grande JP, Garovic V. Renal disorders in pregnancy: core Curriculum 2019. *Am J Kidney Dis*. 2019;73(1):119–130.
46. Mårtensson J, Bellomo R. Perioperative renal failure in elderly patients. *Curr Opin Anaesthesiol*. 2015;28:123–130.
47. Finlay S, Jones MC. Acute kidney injury. *Med (United Kingdom)*. 2013;41(3):182–185.
48. Langham RG, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for acute kidney injury. *Nephrology*. 2014;19(5):261–265.
49. Ishag S, Thakar CV. Stratification and risk reduction of perioperative acute kidney injury. *Anesthesiol Clin*. 2016;34(1):89–99.
50. Cheng YJ, et al. Fluid administration prevents renal dysfunction during hypotension under spinal anesthesia in a rat model. *Acta Anaesthesiol Sin*. 2003;41(1):7–12.
51. Chawla LS, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med*. 2014;371(1):58–66.
52. Evans PD, Taal MW. Epidemiology and causes of chronic kidney disease. *Medicine (Baltim)*. 2011;39(7):402–406.
53. United States Renal Data System. *2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2019.

54. Yean JY, et al. Hemodialysis. In: Yu ASL, et al., eds. *Brenner & Rector's The Kidney*. 11th ed. Philadelphia: Elsevier; 2020:2038–2093.
55. Correa-Rotter R, et al. Peritoneal dialysis. In: Yu ASL, et al., eds. *Brenner & Rector's The Kidney*. 11th ed. Philadelphia: Elsevier; 2020:2094–2118.
56. McLeod DJ, et al. Preoperative risk assessment in children undergoing major urologic surgery. *J Pediatr Urol*. 2016;12l(1):26.e1–26.e7.
57. Gumbert SD, Kork F, Jackson ML, et al. Perioperative acute kidney injury. *Anesthesiology*. 2020;132(1):180–204.
58. Meersch M, et al. Patient with chronic renal failure undergoing surgery. *Curr Opin Anaesthesiol*. 2016;29(3):413–420.
59. Zarbock A, Milles K. Novel therapy for renal protection. *Curr Opin Anaesthesiol*. 2015;28(4):431–438.
60. Zacharis M, et al. Interventions for protecting renal function in the perioperative period. *Cochrane Database Syst Rev*. 2013;9:CD003590.
61. Krishnen A, Levin A. Laboratory assessment of kidney disease: glomerular filtration rate, urinalysis and proteinuria. In: Yu ASL, et al., eds. *Brenner & Rector's The Kidney*. 11th ed. Philadelphia: Elsevier; 2020:732–757.
62. Ahmed FA, Catic AG. Decision-making in geriatric patients with end-stage renal disease: Thinking beyond nephrology. *J Clin Med*. 2018;8(1):5.
63. Sunagawa G, et al. Coronary artery bypass surgery is superior to percutaneous coronary intervention with drug-eluting stents for patients with chronic renal failure on hemodialysis. *Ann Thorac Surg*. 2010;89(6):1896–1900.
64. Aoyama T, et al. Sirolimus-eluting stents vs. bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. *Circ J*. 2008;72(1):56–60.
65. Sud M, Naimark DM. Cardiovascular disease in chronic kidney disease in 2015. *Curr Opin Nephrol Hypertens*. 2016;25(3):203–207.
66. Fox KM, et al. Transfusion burden among chronic kidney disease (CKD) patients not on dialysis. *Am J Kidney Dis*. 2011;57(4):B40.
67. St Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. *BMC Nephrol*. 2018;19(1):67.
68. Tsubakihara Y, et al. 2008 Japanese society for dialysis therapy: guidelines for renal anemia in chronic kidney disease. *Ther Apher Dial*. 2010;14(3):240–275.
69. Karaboyas A, Morgenstern H, Fleischer NL, et al. Inflammation and erythropoiesis-stimulating agent response in hemodialysis patients: a Self-matched longitudinal study of anemia management in the dialysis outcomes and practice patterns study (DOPPS). *Kidney Med*. 2020;2(3):286–296.
70. Brugnara C, Eckardt KU. Hematologic aspects of kidney disease. In: Yu ASL, et al., eds. *Brenner & Rector's The Kidney*. 11th ed. Philadelphia: Elsevier; 2020:1861–1900.
71. Tamura MK. Neurologic aspects of kidney disease. In: Yu ASL, et al., ed. *Brenner & Rectors the Kidney*. 11th ed. Philadelphia: Elsevier; 2020:1916–1931.
72. Carrero JJ, et al. Endocrine aspects of chronic kidney disease. In: Yu ASL, et al., ed. *Brenner & Rectors the Kidney*. 11th ed. Philadelphia: Elsevier; 2020:1901–1915.
73. Shiao CC, et al. Long-term remove organ consequences following acute kidney injury. *Crit Care*. 2015;19:438.
74. Wyne A, et al. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. *Clin J Am Soc Nephrol*. 2011;6(2):326–333. https://doi.org/10.2215/CJN.04770610.
75. Ruchi R, Bozorgmehri S, Ozrazgat-Baslanti T, et al. Opioid safety and Concomitant benzodiazepine Use in end-stage renal disease patients. *Pain Res Manag*. 2019;2019:3865924.
76. Tracy B, Sean Morrison R. Pain management in older adults. *Clin Ther*. 2013;35(11):1659–1668.
77. Agarwal AK. Systemic effects of hemodialysis access. *Adv Chronic Kidney Dis*. 2015;22(6):459–465.
78. Kosa SD, et al. Preoperative vascular access evaluation for haemodialysis patients. *Cochrane Database Syst Rev*. 2015;9:CD007013.
79. Levin SR, Farber A, Malas MB, et al. Association of anesthesia type with outcomes after outpatient Brachiocephalic arteriovenous fistula creation. *Ann Vasc Surg*. 2020;S0890–5096(20):30482–30489.
80. Kwofie K, et al. Standard approaches for upper extremity nerve blocks with an emphasis on outpatient surgery. *Curr Opin Anaesthesiol*. 2013;26(4):501–508.
81. Stone PA, et al. Dialysis access. *Ann Vasc Surg*. 2012;26(5):747–753.
82. Shemesh D, et al. Anesthesia for vascular access surgery. *J Vasc Access*. 2014;15(suppl 7):38–44.
83. Yoo DW, et al. Successful access rate and risk factor of vascular access surgery in arm for dialysis. *Vasc Specialist Int*. 2014;30(1):33–37.
84. Basta M, Sloan P. Epidural hematoma following epidural catheter placement in a patient with chronic renal failure. *Can J Anaesth*. 1999;46(3):271–274.
85. Negi S, et al. Dexmedetomidine versus fentanyl as coadjuvants of balanced anaesthesia technique in renal transplant recipients. *Middle Ease J Anaesthesiol*. 2014;22(6):549–557.
86. Sorin J, Brull SJ, Meistelman C. Pharmacology of neuromuscular drugs. In: Gropper MA, et al., ed. *Miller's Anesthesia*. 9th ed. Philadelphia: Elsevier; 2020:792–832.
87. Rollino C, et al. Is vecuronium toxicity abolished by hemodialysis? A case report. *Artif Organs*. 2000;24(5):386–387.
88. Robertson EN, et al. Pharmacodynamics of rocuronium 0.3 mg/kg in adult patients with and without renal failure. *Eur J Anaesthesiol*. 2005;22(12):929–932.
89. De Souza CM, et al. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: a comparative prospective clinical trial. *Eur J Anaesthesiol*. 2015;32(10):681–686.
90. Ono Y, Fujita Y, Kajiura T, et al. Efficacy and safety of sugammadex in patients undergoing renal transplantation. *JA Clin Rep*. 2018;4(1):56.
91. Cammu G, et al. Dialysbility of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. *Br J Anaesth*. 2012;109(3):382–390.
92. Slocum JL, et al. Marking renal injury: can we move beyond serum creatinine? *Transl Res*. 2012;159(4):277–289.
93. Schindler AW, Marx G. Evidence-based fluid management in the ICU. *Curr Opin Anaesthesiol*. 2016;29(2):158–165.
94. Garrioch SS, Gilles MA. Which intravenous fluid for the surgical patient? *Curr Opin Crit Care*. 2015;21(4):358–363.
95. Van Regenmortel N, et al. Fluid management before, during and after elective surgery. *Curr Opin Crit Care*. 2014;20(4):390–395.
96. Gomelsky A, Abreo K, Khater N, et al. Perioperative acute kidney injury: stratification and risk reduction strategies. *Best Pract Res Clin Anaesthesiol*. 2020;34(2):167–182.
97. Spiro MD, Eilers H. Intraoperative care of the transplant patient. *Anesthesiol Clin*. 2013;31(4):705–721.
98. Tonelli M, et al. Epidemiology and mechanisms of uremia-related cardiovascular disease. *Circulation*. 2016;133(t):518–536.
99. Roberson D, Sperling C, Shah A, Ziemba J. Economic considerations in the management of nephrolithiasis. *Curr Urol Rep*. 2020;21(5):18.
100. Moran CP, Courtney AE. Managing acute and chronic renal stone disease. *Practitioner*. 2016;260(1790):17–20. 2–3.
101. Elmansy HE, Lingeman JE. Recent advances in lithotripsy technology and treatment strategies: a systematic review update. *Int J Surg*. 2016;36(Pt D):676–680.
102. Kirkali Z, et al. Urinary Stone Disease: progress, status, and needs. *Urology*. 2015;86(4):651–653.
103. Raman JD, Pearle MS. Extracorporeal shock wave lithotripsy for ureteral stones. In: Rao NP, et al., ed. *Urinary Tract Stone Disease*. London: Springer; 2011:469–477.
104. Johri N, et al. An update and practical guide to renal stone management. *Nephron Clin Pract*. 2010;116(3).
105. McAteer J, Evan A. The acute and long-term adverse effects of shock wave lithotripsy. *Semin Nephrol*. 2008;28(2):200–213.
106. Elmansy HE, Lingeman JE. Recent advances in lithotripsy technology and treatment strategies: a systematic review update. *Int J Surg*. 2016;36(Pt D):676–680.

107. Behnia R, et al. Hemodynamic and catecholamine responses associated with extracorporeal shock wave lithotripsy. *J Clin Anesth*. 1990;2(3):158–162.
108. Saussine C. Extracorporeal shock wave lithotripsy. *Prog Urol*. 2013;23(14):1168–1171.
109. Gravenstein D. Extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy. *Anesthesiol Clin North America*. 2000;18(4):953–971.
110. Li JK, Teoh JY, Ng CF. Updates in endourological management of urolithiasis. *Int J Urol*. 2019;26(2):172–183.
111. Druskin SC, Ziemba JB. Minimally invasive ("Mini") percutaneous nephrolithotomy: classification, indications, and outcomes. *Curr Urol Rep*. 2016;17(4):30.
112. Hawary A, et al. Transurethral resection of the prostate syndrome: almost gone but not forgotten. *J Endourol*. 2009;23(12):2013–2020.
113. Rieken M, Bachmann A. Laser treatment of benign prostate enlargement-which laser for which prostate? *Nat Rev Urol*. 2014;11(3):142–152.
114. Roberts WW. New technologies in benign prostatic hyperplasia management. *Curr Opin Urol*. 2016;26(3):254–258.
115. Vijayan S. TURP syndrome. *Trends Anaesth Crit Care*. 2011;1(1):46–50.
116. Seif NE, Shehab HA, Elbadawy AM. Prophylaxis versus treatment against transurethral resection of prostate syndrome: the role of hypertonic saline. *Anesth Essays Res*. 2020;14(1):104–111.
117. Kumar V, Vineet K, Deb A. TUR syndrome - a report. *Urol Case Rep*. 2019;26:100982.
118. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. *J Urol*. 2017;197:1565.
119. Ahyai SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. *Eur Urol*. 2010;58(3):384–397.
120. Abboudi H, et al. Learning curves for urological procedures: a systematic review. *BJU Int*. 2014;114(4):617–629.
121. Dissayabutra T, et al. Irrigation with water during transurethral resection of the prostate (TURP) induces intravascular hemolysis. *Asian Biomed*. 2013;7(6):795–802.
122. Lee SW, et al. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: a quality and meta-analysis. *Int Neurourol J*. 2013;17(2):59–66.
123. Olson J, Peters S. Pulmonary edema and cardiac arrest complicating transurethral resection of the prostate and TURP syndrome. *Chest*. 2011;140 (4 MeetingAbstracts):152A.
124. Yousef AA, et al. A randomized comparison between three types of irrigating fluids during transurethral resection in benign prostatic hyperplasia. *BMC Anesthesiol*. 2010;10:7.
125. Wong DH, et al. Incidence of perioperative myocardial ischemia in TURP patients. *J Clin Anesth*. 1996;8(8):627–630.
126. Asthana V. Effect of irrigation fluid temperature on core temperature and hemodynamic changes in transurethral resection of prostate under spinal anesthesia. *Anesth Essays Res*. 2014;8(2):209.
127. Sharma G, Sharma AP, Mavuduru RS, et al. Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis. *World J Urol*. 2020. https://doi.org/10.1007/s00345-020-03201-3.
128. Cornu JN, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. *Eur Urol*. 2015;67(6):1066–1096.
129. Huang AC, et al. The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: technique and outcomes. *Eur Urol*. 2011;59(4):595–603.
130. Malhotra A, Malhotra V. Complications of transurethral surgery. In: Atlee JL, ed. *Complications in Anesthesia*. 3rd ed. Philadelphia: Elsevier; 2018:210–213.
131. Vaghadia H, et al. Selective spinal anesthesia for outpatient transurethral prostatectomy (TURP): randomized controlled comparison of chloroprocaine with lidocaine. *Acta Anaesthesiol Scand*. 2012;56(2):217–223.
132. Abdelmonem A. Low dose hyperbaric bupivicaine injected at T12-L1 provides adequate anesthesia with stable hemodynamics for elderly patients undergoing TURP. *Egypt J Anaesth*. 2011;27(2):95–100.
133. McGowan-Smyth S, Vasdev N, Gowrie-Mohan S. Spinal anesthesia facilitates the early recognition of TUR syndrome. *Curr Urol*. 2016;9(2):57–61.
134. Breda A. Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience. *Eur Urol*. 2009;55(4):836–850.
135. Burgess NA, et al. Randomized trial of laparoscopic v open nephrectomy. *J Endourol*. 2007;21(6):610–613.
136. Wolf JS, et al. The extraperitoneal approach and subcutaneous emphysema are associated with greater absorption of carbon dioxide during laparoscopic renal surgery. *J Urol*. 1995;154(3):959–963.
137. Gundeti MS, et al. Robotic-assisted laparoscopic reconstructive surgery in the lower urinary tract. *Curr Urol Rep*. 2013;14(4):333–341.
138. Cockcroft JO, et al. Anesthesia for major urologic surgery. *Anesthesiol Clin*. 2015;33(1):165–172.
139. Bickel A, et al. Overcoming reduced hepatic and renal perfusion caused by positive-pressure pneumoperitoneum. *Arch Surg*. 2007;142(2):119–124.
140. Yates DR, et al. From Leonardo to da Vinci: the history of robot-assisted surgery in urology. *BJU Int*. 2011;108(11):1708–1714.
141. Hemal A, Babbar P. Robot-assisted urologic surgery in 2010 - advancements and future outlook. *Urol Ann*. 2011;3(1):1.
142. Bivalacqua TJ, et al. Open, laparoscopic and robotic radical prostatectomy: Optimizing the surgical approach. *Surg Oncol*. 2009;18(3):233–241.
143. Chaussy Y, et al. Robot-assisted surgery: current status evaluation in abdominal and urological pediatric surgery. *J Laparoendosc Adv Surg Tech*. 2013;23(6):530–538.
144. Sheth KR, Koh CJ. The future of robotic surgery in pediatric urology: Upcoming technology and Evolution within the field. *Front Pediatr*. 2019;7:259.
145. Navaratnam A, Abdul-Muhsin H, Humphreys M. Updates in Urologic Robot Assisted Surgery. F1000Res. 2018;7:F1000 Faculty Rev-1948. Published 2018 Dec 18.
146. Magheli A, et al. Impact of surgical technique (open vs. laparoscopic vs. robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. *BJU Int*. 2011;107(12):1956–1962.
147. Wang GJ, et al. Robotic vs. open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. *BJU Int*. 2008;101(1):89–93.
148. Gainsburg DM. Anesthetic concerns for robotic-assisted laparoscopic radical prostatectomy. *Minerva Anestesiol*. 2012;78:596–604.
149. Awad H, et al. Anesthetic considerations for robotic prostatectomy: a review of the literature. *J Clin Anesth*. 2012;24(6):494–504.
150. Kalmar AF, et al. Influence of steep Trendelenburg position and CO2 pneumoperitoneum on cardiovascular, cerebrovascular, and respiratory homeostasis during robotic prostatectomy. *Br J Anaesth*. 2010;104(4):433–439.
151. Malhotra V, et al. Anesthesia and the renal and genitourinary system. In: Gropper MA, et al., eds. *Miller's Anesthesia*. 9th ed. Philadelphia: Elsevier; 2020:1931–1959.